Navin Fluorine International Limited has released its Investor Presentation for the second quarter and first half of the Financial Year 2026-27. The presentation details key financial performance highlights, including significant year-over-year growth in Sales, Operating EBITDA, and Operating PBT. It also provides an in-depth look at the performance of its business verticals—HPP, Specialty Chemicals, and CDMO—along with updates on capex programs and strategic initiatives.
Navin Fluorine Unveils Q2 & H1 FY27 Investor Presentation
Navin Fluorine International Limited has officially released its Investor Presentation for the quarter and half-year ended September 30, 2026 (Q2 & H1 of FY 2026-27). The comprehensive document, made available on the company’s website, outlines the company’s performance and strategic direction.
Key Financial Highlights
The presentation showcases strong financial performance for H1 FY27. Sales reached ₹2,235.8 Cr, marking a 51% YoY increase. Operating EBITDA grew by 69% YoY to ₹764.5 Cr, and the Operating EBITDA Margin stood at a healthy 34.2%, up by 367 bps YoY. Operating PBT saw a substantial 93% YoY jump to ₹619.2 Cr.
For Q2 FY27, Sales were reported at ₹1,190.7 Cr, up 57% YoY and 14% QoQ. Operating EBITDA was ₹407.5 Cr (up 66% YoY, 14% QoQ), with an Operating EBITDA Margin of 34.2% (up 176 bps YoY). Operating PBT grew by 87% YoY to ₹336.0 Cr.
Business Vertical Performance
The presentation also highlights the performance across its key business segments:
- HPP (High Performance Products): Revenue for Q2 FY27 was ₹604 Cr, a 49% YoY increase. Key highlights include revenue growth driven by volume and improved realisations, a firm pricing environment for HFC, and an extended HFO supply contract with Solstice Advanced Materials US, Inc., adding potential revenue of ~$180 million.
- Specialty Chemicals: Revenue for Q2 FY27 was ₹348 Cr, up 58% YoY. Growth is underpinned by strong order visibility, a scaling product pipeline, and the commissioning of de-bottlenecking MPP capacity at Dahej. The Chemours project is targeted for completion by end of Q3 FY27.
- CDMO (Contract Development and Manufacturing Organisation): Revenue for Q2 FY27 was ₹239 Cr, a 78% YoY increase. The segment shows strong momentum with positive developments on pipeline molecules and deeper engagement with European CDMO majors. Phase II – cGMP4 capex of ₹125 Cr is on track for operationalization by end Q4 FY27.
Strategic Initiatives and Capex
Navin Fluorine is actively pursuing its strategy of ‘Incubating advanced materials’ focusing on niche applications in high-growth sectors like Data Centers, Electronics, Defence & Semiconductors. The company has outlined several capex projects, including Adoption Capacities (₹90 Crs), Chemours Project (₹120 Crs), and a DRDO project for defence material development. The ongoing capex program includes significant investments in HFC, Chemours Project, Renewable power project, Advanced Materials, and Phase II – cGMP4, with projected peak revenue potential of ₹600-825 Crs per annum for the HFC segment.
Commitment to Sustainability and Governance
The company reiterated its commitment to Sustainable Value Creation through its Environment, Social, and Governance (ESG) framework, guided by principles of Responsible Care (RC) and Pharmaceutical Supply Chain Initiative (PSCI). The presentation outlines progress on ESG goals, including environmental compliance, carbon emission reduction, renewable energy usage, and social initiatives like diversity and inclusion, alongside robust governance practices.
Source: BSE
